Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity
A Phase I Trial
Darryl P. Leong, Tammy Cosman, Muhammad M. Alhussein, Nidhi Kumar Tyagi, Sarah Karampatos, Carly C. Barron, Douglas Wright, Vikas Tandon, Patrick Magloire, Philip Joseph, David Conen, P.J. Devereaux, Peter M. Ellis, Som D. Mukherjee and Sukhbinder Dhesy-Thind
This spaghetti plot demonstrates that all but 2 participants exhibited stable left ventricular ejection fraction (LVEF) while continuing to receive trastuzumab and that the 2 participants who experienced deterioration in left ventricular ejection fraction had improvement in left ventricular ejection fraction after permanently discontinuing trastuzumab.